Exposure Dwell Time to Lethal Agents Required to Achieve a Desired Sterility Assurance Level.

Alfredo Rodriguez, PhD
The National Center for Food
Safety & Technology (NCFST)

IFTPS Annual Meeting 2009 San Antonio, Texas.






Outline

Risk as a significant component of processes

Techniques that may assist to place bounds on risk while defining the exposure dwell to a lethal agent.



Consumers are demanding miracle foods that are totally natural, have zero calories, zero fats and cholesterol, delicious taste, total nutrition, low price, environmentally friendly production, 'green' packaging....and that guarantee perfect bodies, romance and immortality

(Carol Brookins, Global Food and Agriculture Summit, 1999)

Some Recent US Food Safety Issues

August, 2006 E. coli in bagged spinach 204 illnesses, in 26 states, three deaths.

September 2006 Recall of refrigerated carrot juice due to btulinum toxin, 4 cases

September 2006 Salmonella in tomatoes sickened 183 illnesses in 2 states.

December 2006: Iceberg lettuce contaminated with *E. coli* fast food restaurants, 152 illnesses.

February 2007: peanut butter contaminated with *Salmonella* 425 illnesses in 44 states.

March 2007: One hundred brands of pet food distributed nationwide were recalled after illnesses and deaths of cats and dogs due to melamine contamination.

June 2007: Veggie Booty snacks contaminated with Salmonella caused 65 illnesses in 20 states.

Some Recent US Food Safety Issues

June 2007: Ground beef contaminated with *E. coli* caused 14 illnesses leading to a recall of ground beef that had been shipped to 11 western states.

July 2007: Canned chili and meats containing Clostridium botulinum were recalled after causing eight illnesses in three states.

August 2007: Nationwide recall of fresh spinach due to suspected Salmonella containmanition.


September 2007: The second largest beef recall in U.S. history (21.7 million pounds) due to *E. coli* contamination of Frozen Hamburgers and Patties

October 2007: Recall of Turkey and Chicken Pot Pies recalled due to Salmonella contamination, Illnesses in 31

Managing the risk of Innovation'

- The opportunity to influence the success of a new product is greatest ne early stages
- Innovation is about being 'brave' not 'foolish'
- Collaboration in pre-competitive validation stage helps to reduce risk

nportance of the Front-End



Reforms to Managing Food Safety

Command & Control
Prescriptive
Point Testing
Constraint to Innovation

Risk based
Flexible
Through Chain
Supports Innovation
More Complex

New Approaches to Risk Management

ALAR

e 'As low as Reasonable'

BUT:

- Technological capabilities vary
- Idea of 'reasonable' varies

Public Health Based Goals

-eg yearly incidence of Listeriosis below 4 cases/million of pop.


BUT:

- -in terms of population
- -not related to specific foods

The Issue Behind the Issue:

Equivalence: Do two systems of food safety risk management (e.g. inspection, HACCP, processing) provide the same degree of public health protection?

Managing the 'Food Safety Cliff'



Food Safety Objectives


$$H_0 + \Sigma I + \Sigma R \leq FSO$$

- FSO = food safety objective
- H_o = initial level of the hazard
- ΣI = total increase in hazard,through growth or contamination
- ΣR = total death (reduction of hazard; negative number)

Impact of New Risk Management

- Increased flexibility....innovation
- Science based & increased transparency
- Will impact
 - Shared responsibility across chain
 - Stringency of HACCP
 - Micro Criteria more science based
 - Equivalency of new processes

Conclusions, & some Unanswered Questions







How does wet heat kill spores?
How does the cortex control core water content?

What is the state of water in the core?

What is the physical state of core cytoplasm

What is the role of CaDPA in the core?

What is the cause of poor germination kinetics (and the consequent lack of success yndallisation procedures)? (& can it be overcome?)

Can we exploit lysozyme germination?

Can we exploit bacteriocins other than nisin as outgrowth inhibitors?

Can we exploit some aspects of the spore's resistance mechanisms, e.g. for the des ovel, ambient-stable, preservation systems?

NCFST Project: Framework for Setting and Validation of Novel Sterilization Processes

$$H_o - \sum_{i=1}^{n} R_i + \sum_{i=1}^{m} I_i \le FSO$$

 Publication of a white paper addressing the use of new risk management schemes (i.e., ICMSF) for determining performance criteria and validation strategies for sterilization processes utilizing new technologies

Definition: Two events A and B are independent if and only if

$$P(B|A) = P(B)$$

And

$$P(A|B) = P(A)$$

Otherwise A and B are dependent.

Theorem two events are independent if and only if

$$P(A \cap B) = P(A)P(B)$$

Therefore, to obtain the probability that two independent objects will both occur, we simply find the product of their individual probabilities.

Walpole & Myers

One possible way to reach very low probabilities of failure (such as required by sterilization processes) is to take advantage of this theorem:


Start with a bounded low probability of failure for a feasible (worst case condition). This is our subject.

Combine it with the (low) probability that the worst case condition will actually occur.

Distribution analysis.

Skewness

The third moment of a distribution and the first shape parameter. The skewness is measure of the symmetry of the distribution. A skewness of zero means the distribution is symmetrical like the normal distribution shown below:




A skewness value of 1 and above or -1 and below represents a sizable departure from normality. The formula used for estimating the skewness from a set of data is:


$$\frac{n}{(n-1)(n-2)} \quad \frac{\sum_{i=1}^{n} (x_i - \overline{X})^3}{S^3}$$

where n is the sample size, x_i represents the data points, \overline{X} is the average and S is the standard deviation.

A positive skewness means the upper tail is longer than the lower tail like the Largest Extreme Value distribution with a skewness of 1.14 shown below:




A negative skewness means the lower tail is longer than the upper tail like the Smallest Extreme Value distribution with a skewness of -1.14 shown below:




Kurtosis


The fourth moment of a distribution and the second shape parameter. The kurtosis is a measure of the heavy the tails are. The normal distribution, shown below, has a kurtosis of 3:



A kurtosis greater than 3 means the tails are heavier than the normal distribution.



A kurtosis less than 3 means the tails are lighter than the normal distribution like the Uniform distribution with a kurtosis of 1.8 shown below:




A kurtosis value of 4 and above or 2 and below represents a sizable departure from normality. The formula used for estimating the kurtosis from a set of data is:

$$\frac{n(n+1)}{(n-1)(n-2)(n-3)} \quad \frac{\sum_{i=1}^{n} (x_i - \overline{X})^4}{S^4} - \frac{3(3n-5)}{(n-2)(n-3)}$$

where n is the sample size, x_i represents the data points, \overline{X} is the average and S is the standard deviation.

The excess kurtosis = kurtosis -3 This results in the normal

Shape: The largest extreme value family of distributions is made up of three distributions: Fréchet, negative Weibull and largest extreme value. It covers any specified average, standard deviation and any skewness below 5.6051382. Together they form a 3-parameter family of distributions that is represented by a curve on a skewness-kurtosis plot as shown below. The Fréchet distribution covers the portion of the curve with skewness above 1.139547. The negative Weibull distribution covers the portion of the curve with skewness below 1.139547. The largest extreme value distribution handles the remaining case of skewness equal to 1.139547.



Type I: Beta Distribution

• Type II: Special case of beta distribution that is symmetrical

• Type III: Gamma Distribution


Type IV: Region above Type V

• Type V: 3 parameter distribution represented by curve

Type VI: Region between Gamma and Type V

Type VII: Special case of Type IV that is symmetrical

The special cases can be ignored (II and VII). Type I and III are alias for distribution already covered. That leaves Type IV, V and VI as new distributions.



Test of Fit: Two normality tests are performed. When no transformation is selected, these tests are applied directly to data values and test for normality. transformation/distribution is selected, these tests are applied to the transformed values and test for whether the selected distribution fits. The first test is a general test for all departures from normality. The Skewness-Kurtosis All test (SK All) is the default test but the Anderson-Darling test (AD) and Shapiro-Wilks test (SW) are also available. They can be selected using the *Analysis Options* dialog box or the popup menu described below. The p-value and decision are given. The test passes if the p-value > 0.05. The second test is the Skewness-Kurtosis Specific test (SK Spec). This test is designed to only reject for those departures from normality that invalid the tolerance interval and confidence statement relative to the spec limits. Passing this test indicates the statements are valid. Only the pass/fail decision is given. If the normality test fails, one can state: "With 95% confidence the data is not from the normal distribution." If it passes, one can state: "No significant departure from normality was detected."

 $\mathbf{P}_{\mathbf{p}}$

Capability index that compares process variation to the width of the spec limits:

$$P_{p} = \frac{\text{(Upper Spec Limit - Lower Spec Limit)}}{6 \text{ Standard Deviations}}$$

The numerator is the width of the spec limits. The denominator is 6 standard deviations, which can be thought of as the width of the process. For the normal distribution 99.7% of values fall within ± 3 standard deviations of the average or into an interval 6 standard deviations wide. A P_p value of 1 means the process variation fills the spec limits. A P_p of 2 means the specs are twice as wide as the process. The larger P_p is, the better the capability.

 \mathbf{P}_{pk}


Capability index that measure the relative distance to the nearest spec limit:

$$P_{pk} = Minimum \left(\frac{Upper Spec Limit - Average}{3 Standard Deviations}, \frac{Average - Lower Spec Limit}{3 Standard Deviations} \right)$$

The numerator is the distance to the nearest spec limit. For a onesided spec limit (lower spec only or upper spec only) only use the portion of the formula for that spec limit. The denominator is 3 standard deviations, which can be thought of as the half the width of the process. For the normal distribution 99.7% of values fall within ±3 standard deviations of the average or into an interval 6 standard deviations wide. A P_{pk} value of 1 means the distance between the average and the nearest spec limit is 3 standard deviations and thus the process fills this interval and touches the spec limit. A P_{pk} value of 2 means the distance between the average and the nearest spec limit is 6 standard deviations and thus the process fills only half this interval. This leaves a safety margin. The larger P_{pk} is, the better the capability.


	Data Values	þ
1	0.223	
2	0.237	
3	0.200	
4	0.227	
5	0.252	
6	0.215	
7	0.244	
8	0.303	
9	0.341	
10	0.522	
11	0.298	
12	0.200	
13	0.500	
14	0.200	
15	0.522	

Time in minutes needed to reach 3 minutes of Fo



Minutes to reach 3 min. Fo (min) - Penetration


Beta Distribution (0.300343, 0.0960209, 1.774071, 7.396485)



With 99% confidence more than 99% of the values are below 1.66113 With 99% confidence more than 99.9474% of the values are in spec.

Minutes to reach 3 min. Fo (min) - Penetration

sformation = NORMINV(BETADIST(X, 1.03632737221423, 29.0013020670302, (1.66472858429911 - 2.93101754615536/ 2.0), (1.66472858429911 + 2.93101754615536/ 2.0)), (2.66472858429911 + 2.93101754615536/ 2.0), (2.66472858429911 + 2.9310175461556/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.66472858429911 + 2.931017546/ 2.0), (2.664728858429911 + 2.931017546/ 2.0), (2.664728858429911 + 2.931017546/ 2.0), (2.664728858429911 + 2.931017546/ 2.0), (



With 99% confidence more than 99% of the values are below 5.865 With 99% confidence more than 99.9474% of the values are in spec.

Distribution Analyzer 1.2 Validation Package

Contains reproductions of the following two documents:

Report Number: TE-07-2

Protocol Number: TE-07-2

Original documents and supporting evidence are on file at:


Taylor Enterprises, Inc. 5510 Fairmont Rd., Suite A Libertyville, IL 60048 USA

Office: (847) 367-1032 Fax: (847) 367-1037 Email: info@variation.com Web: www.variation.com

Program has been validated and can be used for regulatory submissions to the FDA.

Prediction intervals on fractional exposure data.

Inoculated packs distributed randomly in the load (distribution gradient previously demonstrated to be random) or in the coldest region.




$$b = \begin{pmatrix} 6.1240239542 \\ 0.2006286003 \\ -0.019945765 \end{pmatrix}$$

Coefficients for the quadratic model.

$$\mathsf{RSQUARED} \coloneqq \frac{\mathsf{SSR}}{\mathsf{SSTO}}$$

RSQUARED = 0.898

Coefficient of determination:




Calculate time required to reach logarithmic survivorship of -1 at the upper 99% prediction interval.

Given
$$Iinterp(x_o, UP, t) = -1$$
 timeNeeded99 := Find(t)

timeNeeded99 = 27.051

Exposure99 := ceil(timeNeeded99 - exposureStart)

Exposure99 = 17



Prediction intervals calculated with variable standard deviation.

References

- Bowman, K.O., and L.R. Shenton. 1986. Moment Techniques, in D'Agostino, R.B., and M.A. Stephens Eds. Goodness of Fit Techniques, Marcel Dekeer Inc, New York,pp 329-279.
- Loehle, C. 2006. Global Optimization (for Wolfram's Mathematica). Loehle enterprises, Naperville, IL.
- Oxborrow, G.S., and R. Berube. 1991. Sterility testing validation of sterilization processes and sporocide testing, in Block, S.S., Ed. Disinfection, sterilization and preservation. Lea and Febiger, Philadelphia. Page 1047.
- Taylor, W.A. 2007. Distribution analyzer user's guide. Taylor enterprises, Inc. Libertiville, II.
- Walpole, R. E., and Myers, R.H. 1978. Probability and statistics for engineers and scientists. McMillan Pubishing Company, New York, page 371.